ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,304.72
      0.70%
      US Tech 100
      18,318.00
      0.95%
      Dow Jones
      39,069.59
      0.01%
      Brent Oil
      81.965
      0.00%
      Bitcoin
      69,085.17
      0.81%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cingulate Inc (CINGW)

      7. Cingulate Inc (CINGW) News

      CINGW

      Cingulate (CINGW)

      Cingulate Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CINGW
      DateTimeSourceHeadlineSymbolCompany
      05/24/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CINGWCingulate Inc
      05/23/20245:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CINGWCingulate Inc
      05/21/20249:00AMGlobeNewswire Inc.FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHDNASDAQ:CINGWCingulate Inc
      05/17/20245:01PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CINGWCingulate Inc
      05/13/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
      05/08/20247:15AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CINGWCingulate Inc
      05/08/20247:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
      05/08/20247:00AMGlobeNewswire Inc.Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
      04/30/20245:45AMGlobeNewswire Inc.Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessNASDAQ:CINGWCingulate Inc
      04/16/20245:00PMGlobeNewswire Inc.Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024NASDAQ:CINGWCingulate Inc
      04/01/20248:00AMGlobeNewswire Inc.Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
      03/19/20244:45PMGlobeNewswire Inc.Cingulate to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
      03/06/20246:45AMGlobeNewswire Inc.Cingulate to Attend DCAT Week 2024 in New York CityNASDAQ:CINGWCingulate Inc
      02/13/20246:45AMGlobeNewswire Inc.Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsNASDAQ:CINGWCingulate Inc
      02/06/20244:15PMGlobeNewswire Inc.Cingulate Announces Closing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
      02/02/20249:15AMGlobeNewswire Inc.Cingulate Announces Pricing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
      01/29/20248:00AMGlobeNewswire Inc.Longtime Cingulate Controller Jennifer Callahan Promoted to CFONASDAQ:CINGWCingulate Inc
      01/29/20246:45AMGlobeNewswire Inc.Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketNASDAQ:CINGWCingulate Inc
      12/01/20239:00AMGlobeNewswire Inc.Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)NASDAQ:CINGWCingulate Inc
      11/13/20234:15PMGlobeNewswire Inc.Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
      10/17/20232:22PMGlobeNewswire Inc.Cingulate to Host CNS Key Opinion Leader Panel in New York CityNASDAQ:CINGWCingulate Inc
      09/21/20231:30PMGlobeNewswire Inc.Cingulate Inc. to Present at the LD Micro Main Event XVINASDAQ:CINGWCingulate Inc
      09/13/20234:15PMGlobeNewswire Inc.Cingulate Announces Closing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
      09/11/20239:22AMGlobeNewswire Inc.Cingulate Announces Pricing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
      09/11/20236:00AMGlobeNewswire Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
      09/08/20234:31PMGlobeNewswire Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumNASDAQ:CINGWCingulate Inc
      09/05/20238:00AMGlobeNewswire Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023NASDAQ:CINGWCingulate Inc
      08/14/20234:15PMGlobeNewswire Inc.Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
      07/11/20238:00AMGlobeNewswire Inc.Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
      06/29/20238:00AMGlobeNewswire Inc.Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustNASDAQ:CINGWCingulate Inc
       Showing the most relevant articles for your search:NASDAQ:CINGW